CTRI/2019/05/019049进行中(未招募)2 期
Study of GVDexa regimen as salvage therapy in relapsed/ refractory Hodgkin’s lymphoma
试验速览
- 阶段
- 2 期
- 状态
- 进行中(未招募)
- 发起方
- JIPMER
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Relapsed/ refractory Hodgkin’s Lymphoma having previously received at least 1 line of standard chemotherapy
- •Age 5- 65 years at the time of enrolmemt
- •ECOG performance status 0 to 1
- •Written informed consent for adults over 18 years of age, and consent from parents/ legal guardian for those below 18 years of age
- •Negative serum pregnancy test
- •Female patients in the reproductive age group MUST AGREE TO use suitable contraception during the course of therapy
- •Patients with relapsed or refractory disease following stem cell transplantation are permitted
- •Acceptable bone marrow and organ function at screening as described below:
- •a. ANC more than 1500 per mic.L (without WBC growth factor support)
- •b. Platelet count more than 75,000 per mic.L;
- •c. Hemoglobin more than 9 g per dL
- •d. Total Bilirubin less than 1.5 x ULN;
- •e. AST (SGOT) less than 3 x ULN (less than 5 × ULN if known liver metastases)
- •f. ALT (SGPT) less than 3 x ULN (less than 5 × ULN if known liver metastases)
- •g. Serum creatinine less than 2 mg/dL or a measured creatinine clearance more than 40 mL/min
- •according to Cockcroft-Gault formula
- •Measurable disease must be present either on physical examination or imaging studies; non- measurable disease alone is not acceptable
排除标准
- •f. Human Immunodeficiency Virus (HIV) infection/and or Anti-retroviral therapy and or HCV infection (patients who are anti-HCV positive but have been treated and have undetectable viral load would be permitted to be part of the study).
- •g. Active Hepatitis B infection (in patients who are Hepatitis B carriers, the markers of active infection such as HbeAg and HBV DNA titers must be negative and patients would be continued on appropariate prophylaxis with antivirasl throughout the duration of the study).
- •h. History of allogeneic transplant
- •i. Patient with known peptic ulcer disease/ history of GI perforation due to peptic ulcer in the past.
- •j. Uncontrolled medical conditions including but not limited to diabetes mellitus and hypertension.
- •k. Pre-existing peripheral neuropathy of > grade 1
- •l. Relapse within 6 months of autologous transplant
研究者
相似试验
进行中(未招募)
不适用
PHASE II STUDY ON TREATMENT WITH VELCADE, DEXAMETHASONE AND FOTEMUSTINE IN PATIENTS AFFECTED BY RELAPSED/REFRACTORY MULTIPLE MYELOMA - B-MUDRelapsed/refractory Multiple MyelomaMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2009-011838-10-ITOSPEDALE POLICLINICO S. MATTEO
进行中(未招募)
1 期
An early phase clinical study to investigate the combination of chemotherapy (Gemcitabine) and the study drug Atu027 in patients with advanced or metastatic pancreas cancerEUCTR2012-004429-26-DESilence Therapeutics GmbH
招募中
3 期
Comparison effect of Dexamethasone on pain, nausea and vomiting and restlessness after rhinoplasty.Septorhinoplasty surgery.IRCT20240208060937N1Esfahan University of Medical Sciences70
尚未招募
2 期
Acupuncture and Lung HealthCTRI/2024/06/069538Dr S Sivaranjini
招募中
不适用
Efficacy and safety of combination therapy with tolvaptan and dapagliflozin in patients with acute decompensated heart failure: A randomized controled trialAcute decompensated heart failureJPRN-UMIN000039340Kansai Medical University30
